Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.

Literature DB >> 29094609

Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.

Smita S Joshi¹, Steven B Maron¹, Daniel V Catenacci².

Abstract

Pembrolizumab is a monoclonal antibody directed against PD-1 that is US FDA approved for treatment of advanced PD-L1 positive gastric and gastroesophageal junction adenocarcinoma in patients who have progressed on at least two prior lines of chemotherapy. This article summarizes the clinical evidence regarding safety, tolerability and efficacy of pembrolizumab in this setting. In addition, this article describes the investigational use of pembrolizumab as first- and second-line therapy and in combination with other treatments. Finally, this review compares other checkpoint inhibitors to pembrolizumab for the treatment of this disease, and explores predictive biomarkers of response to PD-1 blockade.

Entities: Chemical Disease Gene Species

Keywords: MK-3475; PD-1; PD-L1; esophageal cancer; esophagogastric cancer; gastric cancer; gastroesophageal cancer; immune checkpoint blockade; immunotherapy; pembrolizumab

Mesh：

Substances：

Year: 2017 PMID： 29094609 PMCID： PMC5827797 DOI： 10.2217/fon-2017-0436

Source DB: PubMed Journal: Future Oncol ISSN： 1479-6694 Impact factor: 3.404

49 in total

Review 1. Pembrolizumab (Keytruda).

Authors: Gerry Kwok; Thomas C C Yau; Joanne W Chiu; Eric Tse; Yok-Lam Kwong
Journal: Hum Vaccin Immunother Date: 2016-07-11 Impact factor: 3.452

2. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial.

Authors: Alicia F C Okines; Sue E Ashley; David Cunningham; Jacqueline Oates; Andrea Turner; Janine Webb; Claire Saffery; Yu Jo Chua; Ian Chau
Journal: J Clin Oncol Date: 2010-08-02 Impact factor: 44.544

Review 3. Update on Gastroesophageal Adenocarcinoma Targeted Therapies.

Authors: Steven B Maron; Daniel V T Catenacci
Journal: Hematol Oncol Clin North Am Date: 2017-06 Impact factor: 3.722

4. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.

Authors: Peter C Thuss-Patience; Manish A Shah; Atsushi Ohtsu; Eric Van Cutsem; Jaffer A Ajani; Hugo Castro; Wasat Mansoor; Hyun Cheol Chung; Gyorgy Bodoky; Kohei Shitara; Gail D Lewis Phillips; Tina van der Horst; Marie-Laurence Harle-Yge; Betsy L Althaus; Yoon-Koo Kang
Journal: Lancet Oncol Date: 2017-03-23 Impact factor: 41.316

5. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.

Authors: J Randolph Hecht; Yung-Jue Bang; Shukui K Qin; Hyun C Chung; Jianming M Xu; Joon O Park; Krzysztof Jeziorski; Yaroslav Shparyk; Paulo M Hoff; Alberto Sobrero; Pamela Salman; Jin Li; Svetlana A Protsenko; Zev A Wainberg; Marc Buyse; Karen Afenjar; Vincent Houé; Agathe Garcia; Tomomi Kaneko; Yingjie Huang; Saba Khan-Wasti; Sergio Santillana; Michael F Press; Dennis Slamon
Journal: J Clin Oncol Date: 2015-11-30 Impact factor: 44.544

6. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Authors: Charles S Fuchs; Jiri Tomasek; Cho Jae Yong; Filip Dumitru; Rodolfo Passalacqua; Chanchal Goswami; Howard Safran; Lucas Vieira Dos Santos; Giuseppe Aprile; David R Ferry; Bohuslav Melichar; Mustapha Tehfe; Eldar Topuzov; John Raymond Zalcberg; Ian Chau; William Campbell; Choondal Sivanandan; Joanna Pikiel; Minori Koshiji; Yanzhi Hsu; Astra M Liepa; Ling Gao; Jonathan D Schwartz; Josep Tabernero
Journal: Lancet Date: 2013-10-03 Impact factor: 79.321

7. Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis.

Authors: M Constanza Camargo; Woo-Ho Kim; Anna Maria Chiaravalli; Kyoung-Mee Kim; Alejandro H Corvalan; Keitaro Matsuo; Jun Yu; Joseph J Y Sung; Roberto Herrera-Goepfert; Fernando Meneses-Gonzalez; Yuko Kijima; Shoji Natsugoe; Linda M Liao; Jolanta Lissowska; Sung Kim; Nan Hu; Carlos A Gonzalez; Yashushi Yatabe; Chihaya Koriyama; Stephen M Hewitt; Suminori Akiba; Margaret L Gulley; Philip R Taylor; Charles S Rabkin
Journal: Gut Date: 2013-04-12 Impact factor: 23.059

Review 8. Clinical significance of tumor-infiltrating lymphocytes for gastric cancer in the era of immunology.

Authors: Byung Woog Kang; Jong Gwang Kim; In Hee Lee; Han Ik Bae; An Na Seo
Journal: World J Gastrointest Oncol Date: 2017-07-15

9. Integrated genomic characterization of oesophageal carcinoma.

Authors:
Journal: Nature Date: 2017-01-04 Impact factor: 49.962

10. Evaluation of dosing strategy for pembrolizumab for oncology indications.

Authors: Tomoko Freshwater; Anna Kondic; Malidi Ahamadi; Claire H Li; Rik de Greef; Dinesh de Alwis; Julie A Stone
Journal: J Immunother Cancer Date: 2017-05-16 Impact factor: 13.751

22 in total

1. Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma.

Authors: Steven B Maron; Leah M Chase; Samantha Lomnicki; Sara Kochanny; Kelly L Moore; Smita S Joshi; Stacie Landron; Julie Johnson; Lesli A Kiedrowski; Rebecca J Nagy; Richard B Lanman; Seung Tae Kim; Jeeyun Lee; Daniel V T Catenacci
Journal: Clin Cancer Res Date: 2019-08-19 Impact factor: 12.531

2. Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma.

Authors: Steven B Maron; Lindsay Alpert; Heewon A Kwak; Samantha Lomnicki; Leah Chase; David Xu; Emily O'Day; Rebecca J Nagy; Richard B Lanman; Fabiola Cecchi; Todd Hembrough; Alexa Schrock; John Hart; Shu-Yuan Xiao; Namrata Setia; Daniel V T Catenacci
Journal: Cancer Discov Date: 2018-02-15 Impact factor: 39.397

Review 3. Dealing with the gray zones in the management of gastric cancer: The consensus statement of the İstanbul Group.

Authors: Erman Aytaç; Fatih Aslan; Bahattin Çicek; Sibel Erdamar; Bengi Gürses; Koray Güven; Okan Falay; Tayfun Karahasanoğlu; Fatih Selçukbiricik; Uğur Selek; Banu Atalar; Emre Balık; Nurdan Tözün; İzzet Rozanes; Ali Arıcan; İsmail Hamzaoğlu; Bilgi Baca; Nil Molinas Mandel; Murat Saruç; Süha Göksel; Gökhan Demir; Fulya Ağaoğlu; Cengiz Yakıcıer; Uğur Özbek; Volkan Özben; Enis Özyar; Ahmet Levent Güner; Özlem Er; Kerim Kaban; Yasemin Bölükbaşı; Dursun Buğra; The İstanbul Group
Journal: Turk J Gastroenterol Date: 2019-07 Impact factor: 1.852

Review 4. Current state of prognostication, therapy and prospective innovations for Barrett's-related esophageal adenocarcinoma: a literature review.

Authors: Sumeet K Mittal; Joe Abdo; Malika P Adrien; Binyam A Bayu; Jay R Kline; Molly M Sullivan; Devendra K Agrawal
Journal: J Gastrointest Oncol Date: 2021-08

5. Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy.

Authors: Katherine I Zhou; Bryan Peterson; Anthony Serritella; Joseph Thomas; Natalie Reizine; Stephanie Moya; Carol Tan; Yan Wang; Daniel V T Catenacci
Journal: Clin Cancer Res Date: 2020-08-20 Impact factor: 12.531

6. Pathological Complete Response After a Single Dose of Anti-PD-1 Therapy in Combination with Chemotherapy as a First-Line Setting in an Unresectable Locally Advanced Gastric Cancer with PD-L1 Positive and Microsatellite Instability.

Authors: Hailong Jin; Peijie Li; Chenyu Mao; Kankai Zhu; Hai Chen; Yuan Gao; Jiren Yu
Journal: Onco Targets Ther Date: 2020-02-26 Impact factor: 4.147